ERBB2 and ovarian cancer: In a research by Li et al. [474], combining anti‐HER2 and anti‐CD47 therapy in both in vivo and in vitro models of ovarian cancer (SKOV3) and breast cancer (BT474) enhanced antitumor activity, reduced the toxicity, and extended survival.